FI3288578T3 - Koostumuksia paksusuolen puhdistukseen ja gastrointestinaalisten häiriöiden hoitoon - Google Patents
Koostumuksia paksusuolen puhdistukseen ja gastrointestinaalisten häiriöiden hoitoon Download PDFInfo
- Publication number
- FI3288578T3 FI3288578T3 FIEP16721609.2T FI16721609T FI3288578T3 FI 3288578 T3 FI3288578 T3 FI 3288578T3 FI 16721609 T FI16721609 T FI 16721609T FI 3288578 T3 FI3288578 T3 FI 3288578T3
- Authority
- FI
- Finland
- Prior art keywords
- peptide
- pain
- pharmaceutically acceptable
- terminus
- colon
- Prior art date
Links
- 210000001072 colon Anatomy 0.000 title claims 8
- 208000018522 Gastrointestinal disease Diseases 0.000 title claims 3
- 239000004615 ingredient Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- 238000000034 method Methods 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- 206010036772 Proctalgia Diseases 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 206010013554 Diverticulum Diseases 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 4
- 150000001413 amino acids Chemical group 0.000 claims 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000012258 Diverticular disease Diseases 0.000 claims 2
- 206010021518 Impaired gastric emptying Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 2
- AXDLCFOOGCNDST-UHFFFAOYSA-N N-Methyltyrosine Chemical group CNC(C(O)=O)CC1=CC=C(O)C=C1 AXDLCFOOGCNDST-UHFFFAOYSA-N 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- WNNNWFKQCKFSDK-UHFFFAOYSA-N allylglycine Chemical compound OC(=O)C(N)CC=C WNNNWFKQCKFSDK-UHFFFAOYSA-N 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 208000001288 gastroparesis Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical group C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims 2
- 208000037911 visceral disease Diseases 0.000 claims 2
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 claims 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 claims 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims 1
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical group [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 claims 1
- XWHHYOYVRVGJJY-QMMMGPOBSA-N 4-fluoro-L-phenylalanine Chemical group OC(=O)[C@@H](N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-QMMMGPOBSA-N 0.000 claims 1
- 206010002153 Anal fissure Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- YPWSLBHSMIKTPR-UHFFFAOYSA-N Cystathionine Natural products OC(=O)C(N)CCSSCC(N)C(O)=O YPWSLBHSMIKTPR-UHFFFAOYSA-N 0.000 claims 1
- 206010011796 Cystitis interstitial Diseases 0.000 claims 1
- ILRYLPWNYFXEMH-UHFFFAOYSA-N D-cystathionine Natural products OC(=O)C(N)CCSCC(N)C(O)=O ILRYLPWNYFXEMH-UHFFFAOYSA-N 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 208000008051 Hereditary Nonpolyposis Colorectal Neoplasms Diseases 0.000 claims 1
- 206010051922 Hereditary non-polyposis colorectal cancer syndrome Diseases 0.000 claims 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims 1
- 206010020853 Hypertonic bladder Diseases 0.000 claims 1
- ILRYLPWNYFXEMH-WHFBIAKZSA-N L-cystathionine Chemical compound [O-]C(=O)[C@@H]([NH3+])CCSC[C@H]([NH3+])C([O-])=O ILRYLPWNYFXEMH-WHFBIAKZSA-N 0.000 claims 1
- 201000005027 Lynch syndrome Diseases 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 1
- 208000030053 Opioid-Induced Constipation Diseases 0.000 claims 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims 1
- 208000000450 Pelvic Pain Diseases 0.000 claims 1
- 206010034310 Penile pain Diseases 0.000 claims 1
- 208000037062 Polyps Diseases 0.000 claims 1
- 206010054048 Postoperative ileus Diseases 0.000 claims 1
- 206010036774 Proctitis Diseases 0.000 claims 1
- 206010036783 Proctitis ulcerative Diseases 0.000 claims 1
- 206010036968 Prostatic pain Diseases 0.000 claims 1
- 108010077895 Sarcosine Proteins 0.000 claims 1
- 206010066218 Stress Urinary Incontinence Diseases 0.000 claims 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046477 Urethral syndrome Diseases 0.000 claims 1
- 208000003728 Vulvodynia Diseases 0.000 claims 1
- 206010069055 Vulvovaginal pain Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000000048 adrenergic agonist Substances 0.000 claims 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 1
- YIYBQIKDCADOSF-UHFFFAOYSA-N alpha-Butylen-alpha-carbonsaeure Natural products CCC=CC(O)=O YIYBQIKDCADOSF-UHFFFAOYSA-N 0.000 claims 1
- 150000001412 amines Chemical group 0.000 claims 1
- 102000016959 beta-3 Adrenergic Receptors Human genes 0.000 claims 1
- 108010014502 beta-3 Adrenergic Receptors Proteins 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 208000013507 chronic prostatitis Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000002052 colonoscopy Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000000741 diarrhetic effect Effects 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 208000023506 generalized abdominal pain Diseases 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 1
- 229960002591 hydroxyproline Drugs 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 208000020629 overactive bladder Diseases 0.000 claims 1
- 229960001639 penicillamine Drugs 0.000 claims 1
- 208000022131 polyp of large intestine Diseases 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 201000007094 prostatitis Diseases 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 229940043230 sarcosine Drugs 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 229960004380 tramadol Drugs 0.000 claims 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims 1
- YIYBQIKDCADOSF-ONEGZZNKSA-N trans-pent-2-enoic acid Chemical compound CC\C=C\C(O)=O YIYBQIKDCADOSF-ONEGZZNKSA-N 0.000 claims 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562156077P | 2015-05-01 | 2015-05-01 | |
| PCT/US2016/030061 WO2016178979A1 (en) | 2015-05-01 | 2016-04-29 | Compositions for colon cleansing and the treatment of gastrointestinal disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3288578T3 true FI3288578T3 (fi) | 2023-05-03 |
Family
ID=55953439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP16721609.2T FI3288578T3 (fi) | 2015-05-01 | 2016-04-29 | Koostumuksia paksusuolen puhdistukseen ja gastrointestinaalisten häiriöiden hoitoon |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10618938B2 (enExample) |
| EP (2) | EP4218789A3 (enExample) |
| JP (5) | JP6930919B2 (enExample) |
| KR (2) | KR20250042844A (enExample) |
| CN (2) | CN114716514A (enExample) |
| CA (2) | CA3172777A1 (enExample) |
| CY (1) | CY1126031T1 (enExample) |
| DK (1) | DK3288578T5 (enExample) |
| EA (1) | EA201792401A1 (enExample) |
| ES (1) | ES2947591T3 (enExample) |
| FI (1) | FI3288578T3 (enExample) |
| HR (1) | HRP20230381T1 (enExample) |
| HU (1) | HUE061954T2 (enExample) |
| LT (1) | LT3288578T (enExample) |
| MA (1) | MA41985B1 (enExample) |
| MD (1) | MD3288578T2 (enExample) |
| MX (2) | MX2017013928A (enExample) |
| PL (1) | PL3288578T3 (enExample) |
| PT (1) | PT3288578T (enExample) |
| RS (1) | RS64160B1 (enExample) |
| SI (1) | SI3288578T1 (enExample) |
| SM (1) | SMT202300114T1 (enExample) |
| WO (1) | WO2016178979A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10618938B2 (en) * | 2015-05-01 | 2020-04-14 | Ironwood Pharmaceuticals, Inc. | Compositions for colon cleansing and the treatment of gastrointestinal disorders |
| SI3464336T1 (sl) | 2016-06-01 | 2022-06-30 | Athira Pharma, Inc. | Spojine |
| CA3238634A1 (en) * | 2021-11-24 | 2023-06-01 | Christopher Leitheiser | Synthetic process for production of modified gcc receptor agonists |
| WO2023097210A1 (en) * | 2021-11-24 | 2023-06-01 | Ironwood Pharmaceuticals, Inc. | Synthetic process for production of modified gcc receptor agonists |
| EP4440595A1 (en) * | 2021-11-29 | 2024-10-09 | Ironwood Pharmaceuticals, Inc. | Pharmaceutical compositions for the treatment of visceral pain |
| WO2026050206A1 (en) * | 2024-08-27 | 2026-03-05 | Ironwood Pharmaceuticals, Inc. | Combinations of glp-1 and guanylate cyclase c (gc-c) receptor agonists |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH689139A5 (de) | 1995-04-03 | 1998-10-30 | Cerbios Pharma Sa | Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung. |
| US5912014A (en) | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
| BR122018074353B8 (pt) * | 2003-01-28 | 2023-05-02 | Ironwood Pharmaceuticals Inc | composição farmacêutica, polipeptídeo e métodos para a produção dos mesmos |
| US7494979B2 (en) * | 2003-06-13 | 2009-02-24 | Ironwood Pharmaceuticals, Inc. | Method for treating congestive heart failure and other disorders |
| EP1940441A4 (en) * | 2005-08-19 | 2010-01-27 | Ironwood Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR TREATING GASTROINTESTINAL DISORDERS |
| US20110172126A1 (en) * | 2008-09-03 | 2011-07-14 | Xenome Ltd | Libraries of peptide conjugates and methods for making them |
| CA2790213A1 (en) * | 2010-02-17 | 2011-08-25 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
| MX357121B (es) * | 2011-03-01 | 2018-06-27 | Synergy Pharmaceuticals Inc Star | Proceso de preparacion de agonistas c de guanilato ciclasa. |
| EP2958577A2 (en) * | 2013-02-25 | 2015-12-30 | Synergy Pharmaceuticals Inc. | Guanylate cyclase receptor agonists for use in colonic cleansing |
| PL3004138T3 (pl) * | 2013-06-05 | 2024-07-29 | Bausch Health Ireland Limited | Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie |
| WO2016015055A1 (en) | 2014-07-25 | 2016-01-28 | Ironwood Pharmaceuticals, Inc. | Colon cleansing compositions |
| US10618938B2 (en) | 2015-05-01 | 2020-04-14 | Ironwood Pharmaceuticals, Inc. | Compositions for colon cleansing and the treatment of gastrointestinal disorders |
-
2016
- 2016-04-29 US US15/570,838 patent/US10618938B2/en active Active
- 2016-04-29 RS RS20230311A patent/RS64160B1/sr unknown
- 2016-04-29 MD MDE20180232T patent/MD3288578T2/ro unknown
- 2016-04-29 JP JP2017557067A patent/JP6930919B2/ja active Active
- 2016-04-29 FI FIEP16721609.2T patent/FI3288578T3/fi active
- 2016-04-29 WO PCT/US2016/030061 patent/WO2016178979A1/en not_active Ceased
- 2016-04-29 KR KR1020257008457A patent/KR20250042844A/ko active Pending
- 2016-04-29 HR HRP20230381TT patent/HRP20230381T1/hr unknown
- 2016-04-29 SI SI201631712T patent/SI3288578T1/sl unknown
- 2016-04-29 CN CN202210288669.XA patent/CN114716514A/zh active Pending
- 2016-04-29 SM SM20230114T patent/SMT202300114T1/it unknown
- 2016-04-29 CN CN201680032088.2A patent/CN108040482B/zh active Active
- 2016-04-29 PT PT167216092T patent/PT3288578T/pt unknown
- 2016-04-29 CA CA3172777A patent/CA3172777A1/en active Pending
- 2016-04-29 MA MA41985A patent/MA41985B1/fr unknown
- 2016-04-29 PL PL16721609.2T patent/PL3288578T3/pl unknown
- 2016-04-29 CA CA2984437A patent/CA2984437C/en active Active
- 2016-04-29 EA EA201792401A patent/EA201792401A1/ru unknown
- 2016-04-29 EP EP23159398.9A patent/EP4218789A3/en active Pending
- 2016-04-29 MX MX2017013928A patent/MX2017013928A/es unknown
- 2016-04-29 LT LTEPPCT/US2016/030061T patent/LT3288578T/lt unknown
- 2016-04-29 ES ES16721609T patent/ES2947591T3/es active Active
- 2016-04-29 DK DK16721609.2T patent/DK3288578T5/da active
- 2016-04-29 HU HUE16721609A patent/HUE061954T2/hu unknown
- 2016-04-29 KR KR1020177034808A patent/KR102783759B1/ko active Active
- 2016-04-29 EP EP16721609.2A patent/EP3288578B8/en active Active
-
2017
- 2017-10-30 MX MX2022013283A patent/MX2022013283A/es unknown
-
2020
- 2020-09-30 JP JP2020165328A patent/JP2020203954A/ja not_active Withdrawn
-
2022
- 2022-07-04 JP JP2022107644A patent/JP2022121734A/ja active Pending
-
2023
- 2023-05-26 CY CY20231100253T patent/CY1126031T1/el unknown
- 2023-12-11 JP JP2023208395A patent/JP7862355B2/ja active Active
-
2024
- 2024-01-26 US US18/424,114 patent/US20240199697A1/en active Pending
-
2025
- 2025-08-12 JP JP2025134346A patent/JP2025169325A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6521977B2 (ja) | 免疫調節剤としての１，２，４−オキサジアゾール誘導体 | |
| JP2023145581A (ja) | インターロイキン－２３受容体のペプチド阻害剤の組成物 | |
| US9073974B2 (en) | RGD-containing cyclic peptides | |
| RU2017146657A (ru) | Пролекарства, содержащие коньюгат гиалуроновой кислоты, ликера и и двойного агониста glp-1глюкагона | |
| HRP20230381T1 (hr) | Pripravci za čišćenje debelog crijeva i liječenje gastrointestinalnih poremećaja | |
| JP2018519254A5 (enExample) | ||
| EA200870449A1 (ru) | Лечение воспалительных и язвенных заболеваний кишечника опиоидными антагонистами | |
| US20150051151A1 (en) | Modified Kisspeptin Peptides and Uses Thereof | |
| WO2023099669A1 (en) | Peptide inhibitors of interleukin-23 receptor | |
| CN104582796A (zh) | 治疗阿尔茨海默病的组合物和方法 | |
| JP2025120320A (ja) | Ｖｉｐｒ２アンタゴニストペプチド | |
| AU2019284019A1 (en) | Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions | |
| JP2022525416A (ja) | ペプチド模倣大環状分子およびその使用 | |
| US12043674B2 (en) | Synthetic cyclic peptides and methods of preparation and use thereof | |
| CN102574904A (zh) | 赋予了经粘膜吸收性的胃动素样肽化合物 | |
| US20120190626A1 (en) | Amyloid beta fibrillogenesis-inhibiting peptide | |
| CN113365627A (zh) | 用于治疗炎症性肠病的vdac抑制剂 | |
| JP2019508419A (ja) | 新規アルファコノトキシンペプチド | |
| JP2025538651A (ja) | 胃腸管及び／又は内分泌障害治療のためのｇａｌｒ２作用剤の用途 | |
| EP4725956A1 (en) | Modified polypeptide and use thereof in field of analgesia | |
| IL324985A (en) | Interleukin-23 receptor peptide inhibitors | |
| TW202440615A (zh) | 介白素－２３受體之肽抑制劑 | |
| CN118201628A (zh) | 丛蛋白a1的跨膜肽拮抗剂及其治疗应用 | |
| HK40069562B (en) | Calcium-sensing receptor agonist compound and application thereof |